Counterpoint: Sentinel lymph node biopsy is not indicated for ductal carcinoma in situ

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 1, Issue 2, 2003, Pages 207-212

  Edge, Stephen B ^a,b   Sheldon, David G ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Breast neoplasms; Carcinoma in situ; Lymph nodes; Sentinel node

Indexed keywords

ARTICLE; BREAST TUMOR; CANCER STAGING; CARCINOMA IN SITU; FEMALE; HUMAN; LYMPH NODE METASTASIS; METHODOLOGY; PAGET NIPPLE DISEASE; PATHOLOGY; SENTINEL LYMPH NODE BIOPSY;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY;

EID: 1842445011     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2003.0019     Document Type: Article

References (50)

1. Pendas S, Dauway E, Giuliano R et al. Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol 2000;7:15-20.
2. Cox CE, Nguyen K, Gray RJ et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): Why map DCIS? Am Surg 2001;67:513-519.
3. Klauber-DeMore N, Tan LK, Liberman L et al. Sentinel lymph node biopsy: Is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000;7:636-642.
4. McMasters KM, Chao C, Wong SL et al. Sentinel lymph node biopsy in patients with ductal carcinoma in situ: A proposal. Cancer 2002;95:15-20.
5. Temple LK, Baron R, Cody HS III et al. Sensory morbidity after sentinel lymph node biopsy and axillary dissection: a prospective study of 233 women. Ann Surg Oncol 2002; 9:654-662.
6. Sener SF, Winchester DJ, Martz CH et al. Lymphedema after sentinel lymphadenectomy for breast carcinoma. Cancer 2001;92:748-752.
7. Fisher B, Jeong JH, Anderson S et al. Twenty-five-year follow- up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347:567-575.
8. Silverstein MJ, Rosser RJ, Gierson ED et al. Axillary lymph node dissection for intraductal breast carcinoma-Is it indicated? Cancer 1987;59:1819-1824.
9. Schwartz GF, Feig SA, Patchefsky AS. Significance and staging of nonpalpable carcinomas of the breast. Surg Gynecol Obstet 1988;166:6-10.
10. Silverstein MJ, Gierson ED, Colburn WJ et al. Axillary lymphadenectomy for intraductal carcinoma of the breast. Surg Gynecol Obstet 1991;172:211-214.
11. Fisher ER, Sass R, Fisher B, Wickerham L et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS). Cancer 1986;57:197-208.
12. Solin LJ, Kurtz J, Fourquet A et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996;14:754-763.
13. Zelis JJ, Sickle-Santanello BJ, Liang WC et al. Do not contemplate invasive surgery for ductal carcinoma in situ. Am J Surg 2002;184:348-349.
14. de Mascarel I, MacGrogan G, Mathoulin-Pelissier S et al. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer 2002;94:2134-2142.
15. Winchester DP, Menck HR, Osteen RT et al. Treatment trends for ductal carcinoma in situ of the breast. Ann Surg Oncol 1995;2:207-213.
16. Lagios MD, Westdahl PR, Margolin FR et al. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 1982;50:1309-1314.
17. Silverstein MJ, Lagios MD, Martino S et al. Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol 1998;16:1367-1373.
18. Fisher B, Costantino J, Redmond C et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993; 328:1581-1586.
19. Sakorafas GH, Tsiotou AG. Ductal carcinoma in situ (DCIS) of the breast: Evolving perspectives. Cancer Treat Rev 2000;26:103-125.
20. The management of ductal carcinoma in situ (DCIS). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Association of Radiation Oncologists. CMAJ 1998;158(Suppl 3):S27-S34.
21. Carlson RW, Anderson BO, Bensinger W et al. NCCN Practice Guidelines for Breast Cancer. Oncology (Huntingt) 2000;14:33-49.
22. Morrow M, Strom EA, Bassett LW et al. Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin 2002;52:256-276.
23. Erickson VS, Pearson ML, Ganz PA et al. Arm edema in breast cancer patients. J Natl Cancer Inst 2001;93:96-111.
24. Petrek JA, Senie RT, Peters M et al. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 2001;92:1368-1377.
25. Kelemen PR, Lowe V, Phillips N. Positron emission tomography and sentinel lymph node dissection in breast cancer. Clin Breast Cancer 2002;3:73-77.
26. van der Hoeven JJ, Hoekstra OS, Comans EF et al. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 2002;236:619-624.
27. Wong SL, Abell TD, Chao C et al. Optimal use of sentinel lymph node biopsy versus axillary lymph node dissection in patients with breast carcinoma: A decision analysis. Cancer 2002;95:478-487.
28. Edge SB, Pass H, Niland J et al. Rapid implementation of sentinel node biopsy for breast cancer at cancer centers (Abstr. #153). Proc Am Soc Clin Oncol 2001;20:39a.
29. Pendas S, Dauway E, Cox CE et al. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients. Am Surg 1999;65:500-505.
30. Sabel MS, Zhang P, Barnwell JM et al. Accuracy of sentinel node biopsy in predicting nodal status in patients with breast carcinoma. J Surg Oncol 2001;77:243-246.
31. Weaver DL, Krag DN, Ashikaga T et al. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: A multicenter study. Cancer 2000;88:1099-1107.
32. Wong SL, Chao C, Edwards MJ et al. The use of cytokeratin staining in sentinel lymph node biopsy for breast cancer. Am J Surg 2001;182:330-334.
33. Dowlatshahi K, Fan M, Anderson JM et al. Occult metastases in sentinel nodes of 200 patients with operable breast cancer. Ann Surg Oncol 2001;8:675-681.
34. Cody HS, Klauber-DeMore N, Borgen P et al. Is it really ductal carcinoma in situ? Ann Surg Oncol 2001;8:617-619.
35. Colpaert C, Vermeulen P, Jeuris W et al. Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J Pathol 2001;193:442-449.
36. Braun S, Cevatli BS, Assemi C et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol 2001;19:1468-1475.
37. Gray RJ, Cox CE, Reintgen DS. Importance of missed axillary micrometastases in breast cancer patients. Breast J 2001;7:303-307.
38. Gebauer G., Fehm T, Merkle E et al. Epithelial cells in lymph nodes or bone marrow do not predict long term outcome in lymph node negative breast cancer patients (Abstr. #147). Proc Am Soc Clin Oncol 2002;21:38a.
39. Cote RJ, Peterson HF, Chaiwun B et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999;354:896-900.
40. Tan LK, Giri D, Panageas K et al. Occult/micrometastases in axillary lymph nodes of breast cancer patients are significant: A retrospective study with long-term follow-up (Abstr. #146). Proc Am Soc Clin Oncol 2002;21:37a.
41. Fitzgibbons PL, Page DL, Weaver D et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-978.
42. Edge SB, Hurd TC. Sentinel node update: Breast cancer. Oncology (Huntingt) 1999;13:213-18.
43. Singletary SE, Allred C, Ashley P et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-3636.
44. Albo D, Wayne JD, Hunt KK et al. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg 2001;182:393-398.
45. Cimmino VM, Brown AC, Szocik JF et al. Allergic reactions to isosulfan blue during sentinel node biopsy-A common event. Surgery 2001;130:439-442.
46. Lagios MD, Silverstein MJ. Sentinel node biopsy for patients with DCIS: A dangerous and unwarranted direction. Ann Surg Oncol 2001;8:275-277.
47. Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: Improved accuracy with directional, vacuum-assisted biopsy. Radiology 1997;202:843-847.
48. Wong SL, Edwards MJ, Chao C et al. The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy. Ann Surg Oncol 2002;9:272-277.
49. Carter BA, Jensen RA, Simpson JF et al. Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol 2000;113:259-265.
50. Tamhane R, Dahlstrom JE, McCallum DD et al. The clinical significance of cytokeratin-positive cells in lymph nodes at the time of mastectomy from patients with ductal carcinomain- situ. Ann Surg Oncol 2002;9:999-1003.